About Variant Bio, Inc.
Variant Bio is a Seattle-based startup that is developing therapies to improve global health by studying the genes of people who are outliers for medically relevant traits. We recently completed our Series A raise and are entering a rapid growth phase. Variant Bio was started because we believe that human genetics has the power to transform drug development. To facilitate this, we have built proprietary genomics and phenotyping platforms that allow us to dramatically reduce the cost of genomic studies and identify genetically-validated targets for therapeutic development.
All of our studies are co-designed with local partners: community groups, academics, and hospitals around the world, and we built Variant Bio from the ground up with ethics at its foundation. We recognize the contribution of our partners through an industry leading benefit-sharing program that dedicates 4% of our revenue and equity value to support local healthcare, sustainable development, education, research, and capacity-building initiatives.
